RxDoctor Payments Data

Elisse Park, MD

Ophthalmology · Fairfield, CTNPI 1366947061

Payments from drug & device makers

$2,450in general payments, 2019–2025

Across 67 payments — averaging $36.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$780
  • Tarsus Pharmaceuticals, Inc.$526
  • Bausch & Lomb Americas Inc.$287
  • AbbVie$195
  • Rayner Intraocular Lenses Limited$144
  • Sun Pharmaceutical Industries Inc.$136
  • plus $382 from 8 others

What the payments were for

  • Food & beverage$2,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,450 in reported general payments places this provider in the 75th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$274,864
Medicare patients
727
Services billed
2,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$66,655
LumiganBimatoprost59$37,874
TyrvayaVarenicline Tartrate21$13,745
Cyclosporine14$9,733
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$8,326
Alphagan PBrimonidine Tartrate15$7,779
Prednisolone Acetate151$5,522
Brimonidine Tartrate29$4,656
Timolol Maleate88$3,886
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha329$3,532
Brinzolamide12$2,430
Latanoprost114$1,359
Doxycycline Hyclate28$383
Dorzolamide Hcl15$369
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$195$112,309131 claims
Oyster Point Pharma, Inc.Tyrvaya$24$13,74521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →